糖尿病肾脏病诊治专家共识

2020-02-04 中华医学杂志,2020,100(4):247-260.

糖尿病肾脏病(DKD)是糖尿病患者的常见慢性并发症之一,是指由糖尿病引起的慢性肾脏病(CKD),表现为尿蛋白水平升高(尿白蛋白肌酐比值≥30 mg/g)和(或)估算肾小球滤过率(eGFR)&lt

中文标题:

糖尿病肾脏病诊治专家共识

发布机构:

发布日期:

2020-02-04

简要介绍:

糖尿病肾脏病(DKD)是糖尿病患者的常见慢性并发症之一,是指由糖尿病引起的慢性肾脏病(CKD),表现为尿蛋白水平升高(尿白蛋白肌酐比值≥30 mg/g)和(或)估算肾小球滤过率(eGFR)<60 ml·min-1·(1.73 m2-1并持续超过3个月,同时排除其他病因CKD而作出的临床诊断。欧美国家大样本糖尿病队列研究报道20%~40%的糖尿病患者可发展为DKD。我国缺乏全国代表性糖尿病队列,一些区域性研究报道的DKD患病率和欧美国家类似。在全球范围内,DKD是CKD[包括终末期肾脏病(ESKD)]的首要病因,亦是糖尿病患者发生心血管疾病和早发死亡的重要危险因素。

 

下载附件:

(因为版权问题,不支持下载)

评论区 (81)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2098936, encodeId=c93320989363f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313f5468438, createdName=ms2000000059632173, createdTime=Mon Nov 07 10:41:50 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227975, encodeId=ec68122e9756f, content=使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/b1b5c82a72ae418f9ebe98e4c5e3b979/8534a2148eab4b5481c40242bed10464.jpg, createdBy=349a5569898, createdName=ms6000000028551923, createdTime=Wed Jun 22 12:16:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053233, encodeId=9b471053233e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0665548467, createdName=ms6000000663297511, createdTime=Mon Sep 20 11:02:05 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995895, encodeId=799499589504, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0b85540563, createdName=ms3000000207098534, createdTime=Sat Jul 03 21:15:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977716, encodeId=c2349e771678, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/3d1db9bb517846b0a124ecf622d79524/4b46394e003240c9bc3ae1940667b827.jpg, createdBy=af715508689, createdName=兰若, createdTime=Mon Jun 28 21:39:53 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2022-11-07 ms2000000059632173

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2098936, encodeId=c93320989363f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313f5468438, createdName=ms2000000059632173, createdTime=Mon Nov 07 10:41:50 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227975, encodeId=ec68122e9756f, content=使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/b1b5c82a72ae418f9ebe98e4c5e3b979/8534a2148eab4b5481c40242bed10464.jpg, createdBy=349a5569898, createdName=ms6000000028551923, createdTime=Wed Jun 22 12:16:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053233, encodeId=9b471053233e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0665548467, createdName=ms6000000663297511, createdTime=Mon Sep 20 11:02:05 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995895, encodeId=799499589504, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0b85540563, createdName=ms3000000207098534, createdTime=Sat Jul 03 21:15:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977716, encodeId=c2349e771678, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/3d1db9bb517846b0a124ecf622d79524/4b46394e003240c9bc3ae1940667b827.jpg, createdBy=af715508689, createdName=兰若, createdTime=Mon Jun 28 21:39:53 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2022-06-22 ms6000000028551923

    使用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2098936, encodeId=c93320989363f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313f5468438, createdName=ms2000000059632173, createdTime=Mon Nov 07 10:41:50 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227975, encodeId=ec68122e9756f, content=使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/b1b5c82a72ae418f9ebe98e4c5e3b979/8534a2148eab4b5481c40242bed10464.jpg, createdBy=349a5569898, createdName=ms6000000028551923, createdTime=Wed Jun 22 12:16:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053233, encodeId=9b471053233e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0665548467, createdName=ms6000000663297511, createdTime=Mon Sep 20 11:02:05 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995895, encodeId=799499589504, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0b85540563, createdName=ms3000000207098534, createdTime=Sat Jul 03 21:15:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977716, encodeId=c2349e771678, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/3d1db9bb517846b0a124ecf622d79524/4b46394e003240c9bc3ae1940667b827.jpg, createdBy=af715508689, createdName=兰若, createdTime=Mon Jun 28 21:39:53 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-09-20 ms6000000663297511

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2098936, encodeId=c93320989363f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313f5468438, createdName=ms2000000059632173, createdTime=Mon Nov 07 10:41:50 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227975, encodeId=ec68122e9756f, content=使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/b1b5c82a72ae418f9ebe98e4c5e3b979/8534a2148eab4b5481c40242bed10464.jpg, createdBy=349a5569898, createdName=ms6000000028551923, createdTime=Wed Jun 22 12:16:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053233, encodeId=9b471053233e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0665548467, createdName=ms6000000663297511, createdTime=Mon Sep 20 11:02:05 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995895, encodeId=799499589504, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0b85540563, createdName=ms3000000207098534, createdTime=Sat Jul 03 21:15:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977716, encodeId=c2349e771678, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/3d1db9bb517846b0a124ecf622d79524/4b46394e003240c9bc3ae1940667b827.jpg, createdBy=af715508689, createdName=兰若, createdTime=Mon Jun 28 21:39:53 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-07-03 ms3000000207098534

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2098936, encodeId=c93320989363f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313f5468438, createdName=ms2000000059632173, createdTime=Mon Nov 07 10:41:50 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227975, encodeId=ec68122e9756f, content=使用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/b1b5c82a72ae418f9ebe98e4c5e3b979/8534a2148eab4b5481c40242bed10464.jpg, createdBy=349a5569898, createdName=ms6000000028551923, createdTime=Wed Jun 22 12:16:11 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053233, encodeId=9b471053233e3, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0665548467, createdName=ms6000000663297511, createdTime=Mon Sep 20 11:02:05 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995895, encodeId=799499589504, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0b85540563, createdName=ms3000000207098534, createdTime=Sat Jul 03 21:15:38 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977716, encodeId=c2349e771678, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210628/3d1db9bb517846b0a124ecf622d79524/4b46394e003240c9bc3ae1940667b827.jpg, createdBy=af715508689, createdName=兰若, createdTime=Mon Jun 28 21:39:53 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-06-28 兰若

    学习了

    0

拓展阅读

2011 糖尿病肾病中医防治指南

中华中医药学会(CACM,China Association of Chinese Medcine) · 2011-02-20

糖尿病肾病防治专家共识(2014年版)

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2014-11-20

中药新药用于糖尿病肾脏疾病临床研究技术指导原则(征求意见稿)

国家药品监督管理局药品审评中心(CDE) · 2019-05-30

SGLT2i对糖尿病肾病治疗获益共识 2020

孟加拉国内分泌协会(Endocrine Society of Bengal) · 2020-10-13

2020 APSN临床实践指南:糖尿病肾病

肾脏病相关专家小组(统称) · 2020-10-25